Abstract
Standard basic therapeutic agents that are approved for the treatment of multiple sclerosis (MS) should be discontinued before pregnancy or when pregnancy occurs at the latest . There is no adequate or only limited data on the effect of these agents on gestation, pregnancy and the fetus or newborn child as well as lactation . The objective of this presentation is to illustrate on the basis of a case report the management of immunomodulatory therapy in female patients with MS from their wish to become pregnant until lactation.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call